Xenon Pharmaceuticals Inc. (XENE) is a clinical-stage, neuroscience-focused biopharmaceutical company, not an ETF. Its stock carries a "Strong Buy" consensus, with the 18 analysts polled by S&P Global averaging a one-year price target of $71.75. That mean rounds to the $72 level used here, and it sits roughly 78% above the latest closing price.
The dispersion is unusually wide, spanning $46 to $90. Recent published targets include Guggenheim at $73 (October 30, 2026), Wells Fargo at $64 (October 30, 2026), H.C. Wainwright at $74 (October 29, 2026), Bank of America at $77 (October 12, 2026), and RBC Capital at $70 (October 1, 2026). Earlier in 2026, firms such as Stifel ($86), J.P. Morgan ($82), Needham ($78), and Deutsche Bank ($90) carried higher targets. The gap between the most cautious and most bullish views reflects how analysts weight the epilepsy opportunity against the setback in the depression program.
Shares closed near $40.42 on November 9, 2026, meaning a move to $72 would require an increase of roughly 78% — a very large advance by any conventional measure. Xenon is a pre-revenue company whose near-term value depends almost entirely on clinical and regulatory outcomes. The share price has already retraced sharply, falling about 38% over the trailing three months from levels near $63, largely in response to a voluntary pause in the major depressive disorder (MDD) studies of azetukalner after neuropsychiatric adverse events were observed.
The path toward the target therefore hinges less on near-term earnings — Xenon posted no meaningful revenue and a trailing-twelve-month net loss of about $409 million — and more on whether the epilepsy indication can be commercialized and whether the psychiatry program can be salvaged.
The central catalyst is azetukalner (XEN1101), a Kv7 potassium-channel opener. Xenon has submitted an NDA to the U.S. FDA for focal onset seizures, supported by positive data from the Phase 2b X-TOLE and Phase 3 X-TOLE2 trials. An approval and successful launch would give the company its first commercial product and a concrete revenue path that most of the higher analyst targets assume.
Xenon's balance sheet is a second support: cash, cash equivalents, and marketable securities totaled roughly $1.2 billion as of June 30, 2026 (about $931 million at the most recent report), funded in part by a March 2026 offering that raised about $707 million. This runway reduces near-term dilution risk. Additional optionality exists in early-stage Nav1.7 pain programs, which several analysts describe as not yet reflected in their models.
The principal obstacle is the paused azetukalner depression program. Analysts trimmed targets after the enrollment pause, and some research removed MDD assumptions from their models entirely. If the psychiatry indication is deprioritized or safety concerns extend to epilepsy, the valuation basis for the highest targets erodes.
Xenon also remains pre-revenue and deeply unprofitable, with EPS (earnings per share) of roughly -$4.74 on a trailing basis. A delayed FDA decision, a Complete Response Letter, manufacturing or launch execution issues, or a broad de-rating of unprofitable biotechnology names would each challenge the path to $72. Continued cash burn, even with a strong balance sheet, is an ongoing factor.
The stock's 52-week range of roughly $33.38 to $72.66 provides useful context: the $72 target sits just below the 52-week high, meaning a full recovery would be needed to reach it. Shares are trading below both the 50-day and 200-day moving averages, signaling a damaged near-term trend after the recent decline. The $63–$66 zone, where the stock traded before the depression-program setback, is a meaningful resistance area, while $33–$34 marks the lower support boundary.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms vary, and no specific horizon is universally stated. For a clinical-stage company, the most important upcoming items are the FDA's acceptance and eventual decision on the azetukalner NDA, quarterly earnings and cash-burn updates, any resolution of the depression-program enrollment pause, and guidance on a potential commercial launch. Analyst revisions around these events are likely to drive the stock more than macroeconomic data.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, news-sensitive name like Xenon, these signals can help traders spot shifting trends and monitor positions more efficiently than manual chart review. Explore the signals to discover opportunities and stay ahead of changing momentum.
Can Xenon Pharmaceuticals reach $72? The $72 figure is the rounded average of 18 analyst targets and implies a very large, roughly 78% move from the latest close near $40.42. Support rests on the submitted epilepsy NDA, a strong cash position, and under-modeled pain assets, while the paused depression program, ongoing losses, and a technically damaged chart represent the main obstacles. With analyst targets spanning $46 to $90, the dispersion is as notable as the average. Whether the stock approaches $72 will depend overwhelmingly on FDA and pipeline developments rather than quarterly fundamentals — making regulatory news and analyst revisions the key items to watch.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, XENE has been loosely correlated with RLMD. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then RLMD could also see price increases.
| Ticker / NAME | Correlation To XENE | 1D Price Change % | ||
|---|---|---|---|---|
| XENE | 100% | -1.26% | ||
| RLMD - XENE | 49% Loosely correlated | +1.20% | ||
| DNTH - XENE | 46% Loosely correlated | -0.72% | ||
| MLTX - XENE | 44% Loosely correlated | -2.87% | ||
| DYN - XENE | 43% Loosely correlated | +0.88% | ||
| REPL - XENE | 42% Loosely correlated | -0.41% | ||
More | ||||